Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 10Prostatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 5Burkitt Lymphoma 5Neoplasms 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Lymphoma, Follicular 3Hodgkin Disease 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Leukemia 2Endometrial Neoplasms 2Down Syndrome 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Myasthenia Gravis 1Lymphoma, T-Cell, Peripheral 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Immunoblastic Lymphadenopathy 1Heart Failure 1Enteropathy-Associated T-Cell Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Prednisolone × 1 year × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡